Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

As COVID-19 Emergencies Ease, Some Progress on Telehealth Rules

A new report from Reason Foundation, Cicero Institute and Pioneer Institute rates every state’s telehealth policy for patient access and ease of providing virtual care. The report highlights telehealth policy best practices for states.

Khan Academy’s Sal Khan & ASU Prep Digital’s Amy McGrath on the Khan World School @ ASU Prep

This week on “The Learning Curve," Cara Candal and Gerard Robinson talk with Sal Khan, founder and CEO of Khan Academy, and Amy McGrath, the Chief Operating Officer of ASU Prep and Deputy Vice President of ASU Educational Outreach.

Pandemic Dead Reckoning: Unseen Casualties of Public Health Interventions

Hubwonk host Host Joe Selvaggi talks with Pioneer Institute’s Senior Fellow Dr. Bill Smith about new evidence that during the past two years of the pandemic, there were as many unseen excess deaths from non-Covid-related diseases as seen from Covid. They discuss the need for public health leaders to pivot their messaging to address this hidden mortality.

Why the jump in non-COVID deaths?

The Wall Street Journal echoes our warning about the rise of non-COVID-related deaths.

Mandate’s Constitutional Collision: Court Offers Civics Lesson with Vaccine Rulings

Hubwonk host Joe Selvaggi talks with Cato Institute Vice President Ilya Shapiro about the recent Supreme Court vaccine mandate rulings and what they tell us about the limits of executive branch power and the sitting justices’ views on the guidance of the U.S. Constitution.

How did COVID impact Massachusetts’ long-term care facilities?

Pioneer Institute has filed a Public Records Act request related to COVID's impact on Massachusetts’ long-term care facilities because the Institute believes this is a matter of obvious importance, both on principle (the public has a right to know the facts), and for purposes of evaluating – and where possible improving – public policy. 

Massachusetts Telehealth Report Card: Are We Embracing Disruption for Better Quality of Care?

Hubwonk host Joe Selvaggi talks with Pioneer Senior Fellow in Healthcare Josh Archambault about his newest research paper, produced with the Cicero Institute and the Reason Foundation, on states' success in implementing telehealth to improve healthcare outcomes. They discuss how Massachusetts has used remote medicine to better reach patients and serve their needs.

Am I Contagious? Divining Covid’s Community Conundrum

Hubwonk host Joe Selvaggi talks with Alva10 CEO and precision medicine expert Hannah Mamuszka about which tests are best for determining who is contagious and the implications for the CDC’s new isolation recommendations.

Virtual Learning Grows During COVID

Virtual learning in K-12 education continues to grow due to the health threat caused by coronavirus variants and the assistance this learning model can provide to at-risk students, according to two papers released today by Pioneer Institute.

COVID Tracker for Long-Term Care Facilities

0 Comments
/
Long Term Care Facilities With 2+ Known COVID Cases and Facility-Reported Deaths in Massachuetts

Face Masks Lifted: Scientists Weigh In With Comprehensive Efficacy Studies

Hubwonk host Joe Selvaggi talks with Harvard Medical School professor, Dr. Jonathan Darrow, about the observations of his recent paper, Evidence for Community Cloth Face Masking to Limit the Spread of SARS-CoV-2: A Critical Review, in which he examines the range, quality, and scientific observations of mask wearing efficacy studies.

Urban Institute’s Dr. Matthew Chingos on the Year of School Choice & the Student Loan Debt Crisis

This week on “The Learning Curve," co-hosts Gerard Robinson and Cara Candal talk with Dr. Matthew Chingos, who directs the Center on Education Data and Policy at the Urban Institute. They discuss the “Year of School Choice,” the welcome 2021 trend of states across America expanding or establishing private school choice programs; as well as the student debt crisis in higher education.